Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Once weekly alendronate.

Philip Sambrook1

  • 1Professor of Rheumatology, University of Sydney, Sydney, Australia. sambrook@med.usyd.edu.au

Drugs of Today (Barcelona, Spain : 1998)
|July 16, 2003
PubMed
Summary
This summary is machine-generated.

Once-weekly alendronate is an effective osteoporosis treatment, matching daily doses in efficacy. This regimen offers improved patient compliance and fewer gastrointestinal issues, making it a convenient alternative.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial.

Journal of bone oncology·2016
Same author

A longitudinal study of knee pain in older men: Concord Health and Ageing in Men Project.

Age and ageing·2013
Same author

Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.

Rheumatology (Oxford, England)·2013
Same author

Editorial.

Therapeutic advances in musculoskeletal disease·2012
Same author

Physical functioning measures and risk of falling in older people living in residential aged care facilities.

Therapeutic advances in musculoskeletal disease·2012
Same author

Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).

Bone·2012
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Pharmacology
  • Bone Metabolism
  • Clinical Therapeutics

Background:

  • Alendronate is a bisphosphonate effective in treating osteoporosis by inhibiting bone resorption.
  • Daily alendronate has demonstrated efficacy in reducing vertebral and hip fractures but can cause upper gastrointestinal symptoms.
  • Osteoporosis management requires effective treatments with favorable safety profiles and patient adherence.

Purpose of the Study:

  • To review published data on the safety and efficacy of once-weekly alendronate administration for osteoporosis.
  • To compare the efficacy and tolerability of weekly versus daily alendronate dosing.
  • To evaluate the benefits of weekly alendronate regarding patient convenience and compliance.

Main Methods:

  • Systematic review of clinical trials and published data on alendronate dosing regimens.

Related Experiment Videos

  • Analysis of safety data, focusing on upper gastrointestinal adverse events.
  • Evaluation of efficacy data, including bone mineral density changes and fracture incidence.

    • Main Results:

    • Once-weekly alendronate demonstrates comparable efficacy to daily dosing in increasing bone mineral density and reducing fractures.
    • Weekly administration is associated with a lower incidence of upper gastrointestinal symptoms compared to daily alendronate.
    • Improved patient compliance and convenience are noted benefits of the once-weekly regimen.

    Conclusions:

    • Once-weekly alendronate is a safe and effective alternative for osteoporosis treatment.
    • The weekly regimen offers significant advantages in patient tolerability and adherence over daily dosing.
    • Weekly alendronate administration represents a valuable option for improving osteoporosis management outcomes.